Vir Biotechnology Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
13.5%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$1.78next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Corporate Update | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
ECLIPSE 1 Phase 3 Trial Topline Data QuarterlyTarget: Topline safety and efficacy data readout
VIR-5818 Phase 1 Dose Escalation Response Data QuarterlyTarget: Initial response data in HER2-expressing solid tumors
Cash, Cash Equivalents, and Investments Quarterly809.3MTarget: Sufficient to fund operations into the second half of 2028
Watch Items
- ECLIPSE 1 Phase 3 Trial ReadoutTrigger: Topline data release in Q4 2026Action: Evaluate efficacy (undetectable HDV RNA) and safety profile of the tobevibart and elebsiran combination regimen to support global regulatory submissions.
- VIR-5818 Phase 1 Response DataTrigger: Data release in H2 2026Action: Assess initial safety, tolerability, and anti-tumor response data in combination with pembrolizumab to validate the PRO-XTEN platform in HER2-expressing solid tumors.
- ECLIPSE 2 and ECLIPSE 3 Phase 3 Trial ReadoutsTrigger: Topline data release in Q1 2027Action: Analyze comparative efficacy and safety data against deferred treatment or bulevirtide to complete the registrational package.
Research as of 19 Jun 2026